JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Search

Embecta Corp

Gesloten

SectorGezondheidszorg

9.21 -0.32

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.04

Max

9.38

Belangrijke statistieken

By Trading Economics

Inkomsten

18M

44M

Verkoop

-2.8M

261M

K/W

Sectorgemiddelde

4.138

60.328

Dividendrendement

6.13

Winstmarge

16.884

Werknemers

1,850

EBITDA

25M

96M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+84.38% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

6.13%

2.24%

Volgende Winsten

5 mei 2026

Volgende dividenddatum

12 jun 2026

Volgende Ex Dividend datum

27 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-79M

569M

Vorige openingsprijs

9.53

Vorige sluitingsprijs

9.21

Nieuwssentiment

By Acuity

40%

60%

135 / 348 Rangschikking in Healthcare

Embecta Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 apr 2026, 23:08 UTC

Winsten
Belangrijke Marktbewegers

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 apr 2026, 23:48 UTC

Marktinformatie

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 apr 2026, 23:42 UTC

Marktinformatie

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 apr 2026, 23:34 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 apr 2026, 23:30 UTC

Marktinformatie

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 apr 2026, 23:08 UTC

Marktinformatie

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 apr 2026, 22:42 UTC

Marktinformatie

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 apr 2026, 22:10 UTC

Winsten

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 apr 2026, 21:56 UTC

Winsten

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 apr 2026, 21:44 UTC

Winsten

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 apr 2026, 21:43 UTC

Winsten

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 apr 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 apr 2026, 20:39 UTC

Winsten

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer Vergelijking

Prijswijziging

Embecta Corp Prognose

Koersdoel

By TipRanks

84.38% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 17 USD  84.38%

Hoogste 22 USD

Laagste 12 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Embecta Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Sentiment

By Acuity

135 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Embecta Corp

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
help-icon Live chat